Part 1:The Basics of Immunization and Vaccines PharMEDium Lunch and Learn Series ProCE, Inc. www.ProCE.com 1 Part 1: The Basics of Immunization and Vaccines December 8, 2017 Featured Speaker: Michael E. Klepser, PharmD, FCCP, FIDP Professor of Pharmacy Practice Ferris State University College of Pharmacy Big Rapids, Michigan LUNCH AND LEARN 2 CE Activity Information & Accreditation ProCE, Inc. (Pharmacist and Tech CE) 1.0 contact hour Funding: This activity is self‐funded through PharMEDium. It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Dr. Klepser is an Advisory Board Member for Melinta Therapeutics and Nabriva, a Consultant for Arkray Diagnostics and PTS Diagnostics, and a Content Developer for NACDS.
29
Embed
Part 1: The Basics of Immunization and Vaccines PharMEDium ...s3.proce.com/res/pdf/PharMEDium2017Dec.pdf · educational presentation. Dr. Klepser is an Advisory Board Member for Melinta
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 1
Part 1: The Basics of Immunization and Vaccines
December 8, 2017
Featured Speaker: Michael E. Klepser, PharmD, FCCP, FIDPProfessor of Pharmacy PracticeFerris State UniversityCollege of PharmacyBig Rapids, Michigan
LUNCH AND LEARN
2
CE Activity Information & Accreditation
ProCE, Inc. (Pharmacist and Tech CE)
1.0 contact hour
Funding: This activity is self‐funded through PharMEDium.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Dr. Klepser is an Advisory Board Member for Melinta Therapeutics and Nabriva, a Consultant for Arkray Diagnostics and PTS Diagnostics, and a Content Developer for NACDS.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 2
3
Submission of an online self‐assessment and evaluation is the only way to obtain CE credit for this webinar
Go to www.ProCE.com/PharMEDiumRx
Print your CE Statement online
Live CE Deadline: January 5, 2018
CPE Monitor– CE information automatically uploaded to NABP/CPE Monitor upon
completion of the self‐assessment and evaluation (user must complete the “claim credit” step)
Online Evaluation, Self-Assessmentand CE Credit
Attendance Code
Code will be provided at the end of today’s activityAttendance Code not needed for On‐Demand
4
Ask a Question
Submit your questions to your site manager.
Questions will be answered at the end of the presentation.
Your question. . . ?
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 3
5
Resources
Visit www.ProCE.com/PharMEDiumRx to access:
– Handouts
– Activity information
– Upcoming live webinar dates
– Links to receive CE credit
6
Part 1: The Basics of Immunization and Vaccines
Michael E. Klepser, PharmD, FCCP, FIDP
Professor
Ferris State University
College of Pharmacy
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 4
7
Learning Objectives
At the conclusion of this presentation, participants will be able to:
1. Describe the differences among various vaccines.
2. Explain how vaccine effectiveness is measured.
3. Discuss the role of adjuvants in vaccines.4. List common side effects and precautions
associated with vaccine administration.5. Discuss Healthy People 2020 with respect to
immunization targets.
8
History of Immunizations
• The transfer of pus from smallpox lesions from an infected individual to a non-infected one was practiced since the 1600s.
• Edward Jenner took pus from a cowpox lesion and vaccinated James Phipps in 1796.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 5
9
History of Immunizations
• The transfer of pus from smallpox lesions from an infected individual to a non-infected one was practiced since the 1600s.
• Edward Jenner took pus from a cowpox lesion and vaccinated James Phipps in 1796.The word vaccine comes from the Latin noun vacca which means cow.
Since Jenner used cowpox material for injections they were called vaccines.
10
History of Vaccines
• Louis Pasteur developed the first laboratory manufactured vaccines.
• Most vaccines used today were developed in the 20th century or later.
• Currently there are vaccines available in the United States against 25 infectious conditions.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 6
11
Currently Approved Vaccines in the United States
• Adenovirus (military only)• Anthrax• Diphtheria• Hepatitis A• Hepatitis B• H. influenzae type b• Human Papillomavirus• Influenza• Japanese Encephalitis• Measles• Meningococcal• Mumps
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 7
13
Impact of Vaccines on World Health
Source: Vaccine 2013. 18;31 (Suppl 2):B61‐72.
14
Immunologic Basics of Vaccinations
• Following exposure to an antigen the body develops an immune response to protect itself.
• Immune responses are divided into:– Innate immune responses
– Adaptive immune responses
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 8
15
Immunologic Basics of Immunization
Innate responses• Rapid and nonspecific• First line of defense• Mediated by:
– Natural killer cells • Recognize and kill virally
infected cells
– Complement• Activated by components
of bacteria
– Phagocytes• Macrophages and
dendritic cells• Ingest foreign particles
Adaptive responses• Specific
• Develops over days
• Long-term immune memory
• Stimulated through immunization
• Mediated by:– T lymphocytes
– B lymphocytes
16
T Lymphocytes
• Subtype of white blood cell• Part of cell-mediated immunity• Types:
– T helper cells: help other WBC in immunologic process (CD4+ T cells)
• Th1 cells: lead to cell-mediated responses
• Th2 cells: produce IL-4 and IL-5 which cause B cells to differentiate into antibody-secreting plasma cells
– Cytotoxic cells: destroy virus-infected and tumor cells (CD8+ T cells)
– Memory T cells: long-lived and can quickly respond to a stimulus
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 9
17
B Lymphocytes
• Subtype of white blood cell
• Part of humoral-mediated immunity
• Types:– Plasma cells: Long-lived, non-
proliferating antibody secreting cells
– Memory B cells: circulate throughout the body and initiate a stronger, more rapid antibody response if they detect the antigen that had activated their parent B cell
18
Antibodies
• Y-shaped protein produced by plasma cells
• Recognize antigens and bind to pathogen to tag it for attack by the immune system or neutralize the target by blocking invasion or impacting survival
• Also called immunoglobulins (Ig)– IgM: Secreted in the early stages of a
immune response
– IgG: Provides the majority of antibody-based immunity
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 10
19
Summary of Key Steps in Generation of Protective Immunity
a. Antigen processing
b. Antigen activation of B cells and complement
c. Activation of antigen presenting cells (APC)
d. Activation of T helper cells
e. T cell-B cell collaboration results in generation of plasma cells and memory B cells
• On first exposure to a vaccine, a primary response is induced and circulating antibodies will appear in 7-10 days.– IgM appear early and have low affinity
– IgG appear later and have high affinity
• Antibody titers peak in 2-6 weeks and then decline
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 11
21
Antibodies
22
Immunologic Basics of Immunization
• After a second exposure to a vaccine, a heightened humoral or cell-mediated response is observed.
• Typically occur within 4-5 days
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 12
23
Antibodies
24
Determinants of Immunogenicity
• Characteristics of the antigen
• Genetic characteristics of the recipient
• Physiologic state of the recipient– Age, nutritional status, sex, pregnancy status,
stress, infections, immune status
• Manner in which the antigen is presented– Route of administration, number of doses, timing
of doses, presence of adjuvants, conjugation
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 13
25
Response to Vaccines
• Serologic response– Response to vaccines, seroconversion, gauged
by measuring the appearance and concentration of antibodies.
• Only assesses humoral immunity
– Duration of immunity is assessed by persistence of antibodies.
• May not be reliable
– Opsonophagocytic activity is used to assess functional antibodies.
26
Response to Vaccines
• Clinical protection– Vaccine effectiveness
• Calculate the risk of disease among vaccinated and unvaccinated persons and determine reduction in risk.
Vaccine Effectiveness
=Risk among unvaccinated group – Risk among vaccinated group
Risk among unvaccinated group
• Recommended vaccine effectiveness for universal use of a vaccine in children is defined as > 80% following a primary series.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 14
27
Improving Response to Vaccines
• An adjuvant is a substance used in combination with an antigen to produce a more robust immune response.– Depot effect
– Up-regulation of cytokines and chemokines
– Cellular recruitment at injection site
– Increased antigen uptake and presentation of antigen presenting cells (APC) which express pattern recognition receptors (PRR)
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 17
33
Examples of Conjugated Vaccines
• Pneumococcal
• Haemophilus influenzae type b
• Meningococcal
Source: Clutterbuck EA. JID 2015; 205: 1408-16.
34
Types of Vaccines
Live Attenuated Vaccines
• Contained live but weakened bacteria or virus
• Risk of causing disease
• Stimulate an immune response similar to the actual disease
• Durable immunity
Inactivated Vaccines
• Contain killed whole microbes, toxoids, or antigenic subunits
• Cannot cause active disease
• Immunity tends to wane
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 18
35
Live Vaccines
• Made by passing the pathogen through a series of cell cultures to diminish the pathogenicity.
• Examples:– Measles, mumps, rubella
– Rotavirus
– Small pox
– Varicella
– Yellow fever
– Zoster (Zostavax)
36
Inactivated/Killed Vaccines
• Made exposing the pathogen to heat or chemicals such as formaldehyde or formalin.– Destroys the ability to replicate but keeps it intact
to stimulate the immune system.
• Examples:– Hepatitis A
– Polio
– Rabies
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 19
37
Toxoid Vaccines
• Inactivating the toxin with heat or chemicals such as formaldehyde or formalin.– Destroys the ability to cause symptoms but keeps
it intact to stimulate the immune system.
• Examples:– Diphtheria
– Tetanus
38
Subunit Vaccines
• Contain fractions of the pathogen that provoke a response from the immune system.
• Examples:– Haemophilus influenzae type b
– Hepatitis B
– Human papillomavirus
– Meningococcal
– Pertussis
– Pneumococcal
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 20
39
Vaccine Components
• Antigen
• Suspending fluid
• Preservatives, stabilizers, and antibiotics– Inhibit or prevent bacterial growth
• Thiomerosal is a mercury-based preservative. Now removed from most childhood vaccines.
– Stabilize the antigen
• Adjuvants
40
General Rule for Administration of Vaccines
Antigen combination Recommended minimum interval between doses
Two or more inactivated Simultaneously or at any interval
Inactivated and live Simultaneously or at any interval
Two or more live 28-day minimum interval, if not administered simultaneously
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 21
41
General Rule for Administration of Vaccines
• Exceptions to the rule:– Do not administer conjugated pneumococcal vaccine
with the conjugated meningococcal vaccine to asplenic patients. Results in decreased response to the pneumococcal vaccine. Recommendation is to administer the pneumococcal vaccine followed by the meningococcal vaccine 4-weeks later.
– Do not administer the different pneumococcal vaccines (PCV13 and PPSV) together. There is a better immune response when PCV13 is administered first.
42
General Rule for Administration of Vaccines
• Exceptions to the rule:– Oral typhoid and rotavirus vaccines may be
administered with or at any interval before or after any other inactivated or live injectable vaccines.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 22
43
Routes of Vaccine Administration
• Intramuscular and subcutaneous administration results in primarily an IgG response.– Intradermal administration may be
more efficient and require less antigen to be administered. Possibly related to direct antigen delivery to the draining lymph nodes.
• Oral and nasal delivery produce a local IgA and general IgG response.
44
Precautions with Administering Vaccines
• Allergic reaction to antigens or other vaccine components.
• Immunocompromised patients– Poor response
– Possibility of not controlling replication (live)
• Coadministration with antibiotics, antivirals, or immunoglobulins (live)
• Pregnancy
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 23
45
Monitoring Vaccine Side Effects
• Observed during clinical trials– Only detects adverse events that occur relatively
frequently (1 per 1,000 doses or higher).
• Post-marketing– Vaccine Adverse Event Reporting System (VAERS)
• An early warning system to detect possible safety issues with U.S. vaccines by collecting information about adverse events that occur after vaccination.
– Vaccine Safety Datalink (VSD)• Conducts vaccine safety studies based on questions or
concerns raised from the medical literature and reports to the VAERS.
46
Vaccine Side Effects
• Vaccines stimulate an immune response– Fever and aches are common
• Vary with vaccine– Range from mild injection site reactions to death
– Vaccines with highest risk of severe adverse reactions:
• Small pox, Yellow fever
– Guillain-Barre Syndrome• Rapid-onset muscle weakness caused by the immune
system damaging the peripheral nervous system.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 24
47
Vaccine Recommendations
• Advisory Committee on Immunization Practices (ACIP)– Composition
• 15 voting members, 8 ex officio members from federal agencies, and 30 non-voting liaisons
– Purpose is to develop recommendations on the use of vaccines in the civilian population of the United States.
• Populations recommended to receive immunizations have increased.
• Immunization schedules have become more complicated.
Part 1: The Basics of Immunization and VaccinesPharMEDium Lunch and Learn Series
ProCE, Inc.www.ProCE.com 27
53
Vaccine Goals
• Health goals for the United States are set each decade by the Department of Health and Human Services.– Aims to reach four overarching goals: Attain high-
quality, longer lives free of preventable disease, disability, injury, and premature death.
54
Healthy People 2020 Vaccination Goals
Pneumococcal vaccine: 90% of adults > 65 years of age